{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T13:09:57Z","timestamp":1771333797233,"version":"3.50.1"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T00:00:00Z","timestamp":1604448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1AI068632"],"award-info":[{"award-number":["UM1AI068632"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1AI068616"],"award-info":[{"award-number":["UM1AI068616"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1AI106716"],"award-info":[{"award-number":["UM1AI106716"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["HHSN275201800001I"],"award-info":[{"award-number":["HHSN275201800001I"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Tuberculosis (TB-)-preventive therapy (TPT) among pregnant women reduces risk of TB in mothers and infants, but timing of initiation should consider potential adverse effects. We propose an analytical approach to evaluate the risk\u2013benefit of interventions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A novel outcome measure that prioritizes maternal and infant events was developed with a 2-stage Delphi survey, where a panel of stakeholders assigned scores from 0 (best) to 100 (worst) based on perceived desirability. Using data from TB APPRISE, a trial among pregnant women living with human immunodeficiency virus (WLWH) that randomized the timing of initiation of isoniazid, antepartum versus postpartum, was evaluated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The composite outcome scoring\/ranking system categorized mother\u2013infant paired outcomes into 8 groups assigned identical median scores by stakeholders. Maternal\/infant TB and nonsevere adverse pregnancy outcomes were assigned similar scores. Mean (SD) composite outcome scores were 43.7 (33.0) and 41.2 (33.7) in the antepartum and postpartum TPT initiation arms, respectively. However, a modifying effect of baseline antiretroviral regimen was detected (P\u2005=\u2005.049). When women received nevirapine, composite scores were higher (worse outcomes) in the antepartum versus postpartum arms (adjusted difference, 14.3; 95% confidence interval [CI], 2.4\u201326.2; P\u2005=\u2005.02), whereas when women received efavirenz there was no difference by timing of TPT (adjusted difference, .62; 95% CI, \u22123.2\u20136.2; P\u2005=\u2005.53).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>For TPT, when used by otherwise healthy persons, preventing adverse events is paramount from the perspective of stakeholders. Among pregnant WLWH in high-TB-burden regions, it is important to consider the antepartum antiretroviral regimen taken when deciding when to initiate TPT.<\/jats:p>\n                  <jats:p>Clinical Trials Registration. NCT01494038 (IMPAACT P1078).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciaa1674","type":"journal-article","created":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T20:13:10Z","timestamp":1603915990000},"page":"e587-e593","source":"Crossref","is-referenced-by-count":3,"title":["Using a Composite Maternal\u2013Infant Outcome Measure in Tuberculosis-Prevention Studies Among Pregnant Women"],"prefix":"10.1093","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6866-4335","authenticated-orcid":false,"given":"Grace","family":"Montepiedra","sequence":"first","affiliation":[{"name":"Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soyeon","family":"Kim","sequence":"additional","affiliation":[{"name":"Frontier Science Foundation, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Weinberg","sequence":"additional","affiliation":[{"name":"University of Colorado, Denver, Colorado, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard","family":"Theron","sequence":"additional","affiliation":[{"name":"Stellenbosch University, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy R","family":"Sterling","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvia M","family":"LaCourse","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Bradford","sequence":"additional","affiliation":[{"name":"FHI 360, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nahida","family":"Chakhtoura","sequence":"additional","affiliation":[{"name":"National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Jean-Philippe","sequence":"additional","affiliation":[{"name":"National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Evans","sequence":"additional","affiliation":[{"name":"The George Washington University, Washington, DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amita","family":"Gupta","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,11,4]]},"reference":[{"key":"2021080205163136900_CIT0001","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1093\/cid\/cis732","article-title":"Tuberculosis in pregnant and postpartum women: epidemiology, management, and research gaps","volume":"55","author":"Mathad","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2021080205163136900_CIT0002","first-page":"S49","article-title":"Revisiting the burden of TB in pregnant and post-partum women (abstract SP-53-C6). Abstract book: 50th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (The Union)","volume":"23","author":"Mafirakureva","year":"2019","journal-title":"Int J Tuberc Lung Dis"},{"key":"2021080205163136900_CIT0003","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1164\/rccm.201106-1083OC","article-title":"Risk of tuberculosis in pregnancy: a national, primary care-based cohort and self-controlled case series study","volume":"185","author":"Zenner","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2021080205163136900_CIT0004","volume-title":"Latent tuberculosis infection: updated and consolidated guidelines for programmatic management","year":"2018"},{"key":"2021080205163136900_CIT0005","doi-asserted-by":"crossref","first-page":"783528","DOI":"10.1155\/2011\/783528","article-title":"Clinical therapeutics in pregnancy","volume":"2011","author":"Feghali","year":"2011","journal-title":"J Biomed Biotechnol"},{"key":"2021080205163136900_CIT0006","doi-asserted-by":"crossref","first-page":"S437","DOI":"10.1093\/cid\/ciu709","article-title":"Designing drug trials: considerations for pregnant women","volume":"59","author":"Sheffield","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2021080205163136900_CIT0007","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/sim.4780100904","article-title":"Three measures for simultaneously evaluating benefits and risks using categorical data from clinical trials","volume":"10","author":"Chuang-Stein","year":"1991","journal-title":"Stat Med"},{"key":"2021080205163136900_CIT0008","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1002\/sim.3923","article-title":"Generalized pairwise comparisons of prioritized outcomes in the two-sample problem","volume":"29","author":"Buyse","year":"2010","journal-title":"Stat Med"},{"key":"2021080205163136900_CIT0009","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/eurheartj\/ehr352","article-title":"The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities","volume":"33","author":"Pocock","year":"2012","journal-title":"Eur Heart J"},{"key":"2021080205163136900_CIT0010","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/cid\/civ495","article-title":"Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR)","volume":"61","author":"Evans","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2021080205163136900_CIT0011","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/0197-2456(92)90020-Z","article-title":"A method of assigning scores to the components of a composite outcome: an example from the MITI trial","volume":"13","author":"Hallstrom","year":"1992","journal-title":"Control Clin Trials"},{"key":"2021080205163136900_CIT0012","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1177\/0962280211436004","article-title":"Impact of weighted composite compared to traditional composite endpoints for the design of randomized controlled trials","volume":"24","author":"Bakal","year":"2015","journal-title":"Stat Methods Med Res"},{"key":"2021080205163136900_CIT0013","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1080\/19466315.2016.1207561","article-title":"Using outcomes to analyze patients rather than patients to analyze outcomes: a step toward pragmatism in benefit:risk evaluation","volume":"8","author":"Evans","year":"2016","journal-title":"Stat Biopharm Res"},{"key":"2021080205163136900_CIT0014","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/sim.7147","article-title":"Weighted analysis of composite endpoints with simultaneous inference for flexible weight constraints","volume":"36","author":"Duc","year":"2017","journal-title":"Stat Med"},{"key":"2021080205163136900_CIT0015","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1177\/1740774520941441","article-title":"Methodologies for pragmatic and efficient assessment of benefits and harms: application to the SOCRATES trial","volume":"17","author":"Evans","year":"2020","journal-title":"Clin Trials"},{"key":"2021080205163136900_CIT0016","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/cid\/ciy766","article-title":"Good studies evaluate the disease while great studies evaluate the patient: development and application of a desirability of outcome ranking endpoint for staphylococcus aureus bloodstream infection","volume":"68","author":"Doernberg","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021080205163136900_CIT0017","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/cid\/ciz784","article-title":"Applying a risk-benefit analysis to outcomes in tuberculosis clinical trials","volume":"70","author":"Miyahara","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021080205163136900_CIT0018","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/1471-0528.13764","article-title":"Development of composite outcomes for individual patient data (IPD) meta-analysis on the effects of diet and lifestyle in pregnancy: a Delphi survey","volume":"123","author":"Rogozinska","year":"2016","journal-title":"BJOG"},{"key":"2021080205163136900_CIT0019","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa1813060","article-title":"Isoniazid preventive therapy in HIV-infected pregnant and postpartum women","volume":"381","author":"Gupta","year":"2019","journal-title":"N Engl J Med"},{"key":"2021080205163136900_CIT0020","doi-asserted-by":"crossref","first-page":"e1000393","DOI":"10.1371\/journal.pmed.1000393","article-title":"Using the Delphi technique to determine which outcomes to measure in clinical trials: recommendations for the future based on a systematic review of existing studies","volume":"8","author":"Sinha","year":"2011","journal-title":"PLoS Med"},{"key":"2021080205163136900_CIT0021","author":"US Department of Health and Human Services; National Institutes of Health; National Institute of Allergy and Infectious Diseases; Division of AIDS"},{"key":"2021080205163136900_CIT0022","doi-asserted-by":"crossref","first-page":"e784","DOI":"10.1093\/cid\/ciaa1482","article-title":"Risk factors for adverse pregnancy outcomes associated with isoniazid preventive therapy in women living with HIV","volume":"72","author":"Theron","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2021080205163136900_CIT0023","first-page":"e25547","volume-title":"Risk factors for hepatotoxicity in HIV-infected women receiving isoniazid preventive therapy in pregnancy and postpartum","author":"Gupta","year":"2020"},{"key":"2021080205163136900_CIT0024","doi-asserted-by":"crossref","DOI":"10.1017\/CBO9780511753831","volume-title":"Stated choice methods: analysis and applications","author":"Louviere","year":"2000"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa1674\/38247341\/ciaa1674.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/3\/e587\/39508516\/ciaa1674.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/3\/e587\/39508516\/ciaa1674.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T05:17:00Z","timestamp":1627881420000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/73\/3\/e587\/5955952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,4]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,11,4]]},"published-print":{"date-parts":[[2021,8,2]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa1674","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,8,1]]},"published":{"date-parts":[[2020,11,4]]}}}